Kornimate/medical-research-clean huggingface dataset:
the effects of acupressure on pain, swelling and comfort in patients with femoral fracture surgery

Conditions: Acupressure

Summary: pain is a subjective and unpleasant sensory and emotional experience associated with actual or potential tissue damage. fractures result from a disruption in the continuity of bone, where bones are subjected to traction, twisting, or compression, causing damage to the surrounding muscular tissues. the treatment of displaced or complex fractures typically requires internal fixation surgery. 89% of fracture patients experience postoperative pain and swelling by the second day following open reduction and internal fixation surgery. these negative sensations can lead to increased pain, limb deformity, and neurovascular compression injuries. if postoperative pain is not adequately managed, it can affect wound healing, increase metabolism and oxygen consumption, and place additional strain on cardiopulmonary function. it is necessary to integrate alternative, non-pharmacological, non-invasive pain relief measures. effectively and safely alleviating acute postoperative pain can enhance comfort, promote early mobilization, improve adherence to postoperative physical therapy, enhance quality of life and shorten hospital stays.


Eligibility criteria:
inclusion criteria: 1. the patient was hospitalized due to injuries from an accident, diagnosed with unilateral femoral fracture and underwent open reduction internal fixation surgery, hemiarthroplasty, and total hip arthroplasty. 2. adults aged 18 years or older. 3. conscious and able to communicate in mandarin or taiwanese (min nan). 4. intact and without missing lower limbs. 5. willing to sign the informed consent form after being briefed on the study objectives and procedures. exclusion criteria: 1. diagnosis of musculoskeletal tumors. 2. history of cerebrovascular accident or peripheral vascular neuropathy. 3. major medical conditions such as cirrhosis, renal failure, heart failure, cancer, and severe brain diseases. 4. edema caused by nutritional deficiency or mucinous causes. 5. pregnant or lactating women. 6. patients using patient-controlled analgesia post-surgery. 7. severe psychiatric disorders or perceptual disorders. 8. platelet count less than 20 x 10\^3/ul before screening. 9. albumin less than 3.5g/dl before screening. 10. individuals closely related to the trial personnel, such as immediate family or dependents of the principal investigator.
study of craniospinal irradiation with linac based volumetric modulated arc therapy (vmat) for patients with leptomeningeal metastasis

Conditions: Leptomeningeal Metastasis

Summary: the purpose of this study is to confirm the safety and efficacy of linac based volumetric modulated arc therapy (vmat) for craniospinal irradiation (csi) in solid tumor cancer patients with leptomeningeal metastasis. the primary aim is to determine if linac based vmat csi for leptomeningeal metastasis improves central nervous system (cns) progression free survival (pfs) compared to the historical standard control cns pfs in patients treated with involved field radiation therapy (ifrt).


Eligibility criteria:
inclusion criteria: 1. solid tumor cancer primary with leptomeningeal metastases established radiographically and/or by csf cytology 2. candidate for radiation therapy for the treatment of leptomeningeal metastases 3. if patient had prior radiation, a treatment plan can be generated that will not exceed normal tissue tolerances 4. patient must have reasonable systemic treatment options, as confirmed by their medical oncologist 5. age ≥ 18 years old 6. able to provide informed consent 7. karnofsky performance scale (kps) ≥ 60 8. adequate hematologic baseline 1. hemoglobin \> 8g/dl 2. absolute neutrophil count \>1,000/mm3 3. platelet count \> 100,000/mm3 9. female subjects must either be of 1. non-reproductive potential (over 60 years old, or without menses for at least 1 year without an alternative medical cause) 2. have history of hysterectomy, bilateral tubal ligation, or bilateral oophorectomy 3. must have negative serum/urine pregnancy test 4. if of reproductive age, must practice effective contraceptive method exclusion criteria: 1. patient has multiple severe neurologic deficits per physician assessment 2. patient has diffuse systemic disease without reasonable systemic therapy options 3. patient is unable to undergo mri brain and spine with gadolinium contrast 4. prior radiation that would preclude development of a treatment plan that respects normal tissue constraints 5. pregnant or lactating women 6. prisoners
mr fingerprinting for diagnostic of prostate cancer

Conditions: Prostate Cancer; Magnetic Resonance Imaging

Summary: the diagnostic pathway for suspected prostate cancer relies greatly on radiological imaging. establishment of magnetic resonance fingerprinting (mrf) has the potential to significantly improve patient experience and outcomes. mrf is a novel and innovative approach to a long-standing challenge of recording and reconstructing mr image the aim is to conduct a clinical pilot study in which patients will be scanned using the newly refined mrf sequence in addition to the conventional scanning protocols.

the patient is at the center of all medical interventions and innovations. for those with prostate cancer, the pathway for new patients has scope for improvement. mri is an important and necessary part of that pathway, but scanning capacity is often stretched, and there is need for effective and efficient scan techniques. beyond mere detection of lesions, the modality has potential to differentiate and categorize the clinical significance of prostate cancer. by virtue of quantitative imaging, the determination of biomarkers could lead to a non-invasive method of prostate cancer diagnosis. the prostate imaging reporting and data system (pirads) scoring is a standardized system of acquiring and categorizing multi-parametric-mr images (mp-mri) of the prostate. the pirads system works to grade to clinical significance of prostate cancer, however this relies on qualitative information. patients referred for a typical mri of the prostate will in addition receive the mr fingerprinting scan, which will add about 8 minutes to their time on the scanner. the direct comparison of the fingerprint maps and multi-parametric images can then be made. conclusions will be drawn with focus to potential improvement of the pirads protocol. the main aim of the project is therefor to implement, validate, and optimize sequences for mr fingerprinting of the prostate.

Eligibility criteria:
inclusion criteria: - men referred to an mr examination for prostate cancer diagnostic exclusion criteria: - none

Keywords: mr fingerprinting prostate cancer
health status evaluation for cancer survivors by non-intrusive sensing system

Conditions: Cancer

Summary: to improve quality of life of elderly cancer survivors 1. using physical activity and environmental sensing technology 2. monitoring physiological indicators of cancer recurrence * analyzing the patient's circadian rhythm, frailty and his/her vital sign. * vital sign includes blood pressure, weight and hrv. 3. collecting the patient information in real time * giving alarm information to the patient, if any special cases our system found. * giving circadian rhythm report to the patient. * giving healthy report to the patient, collected from his/her vital sign.


Eligibility criteria:
inclusion criteria: * the clinical pathology and diagnostic imaging to determine the cancer who completed acute treatment, and patients with more than a month recuperating. * over 65 years old. * proficient in chinese or taiwanese. * normal cognitive function exclusion criteria: * no history of cancer * over 65 years old. * proficient in chinese or taiwanese. * normal cognitive function

Keywords: cancer survivors circadian rhythm elderly patients frailty
tailored videos to reduce tobacco smoke exposure among pregnant women and newborns

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: the purpose of this study is to develop and evaluate the efficacy of five tailored dvds in reducing exposure to environmental tobacco smoke (ets) among low income pregnant/postpartum women.

background: the healthy people 2010 objectives address the importance of smoking cessation during pregnancy and the importance of reducing ets exposure among children and adults. this study will use a new combination of existing technologies to maximize the appropriateness of prenatal and postpartum education concerning ets exposure in an innovative, inexpensive, and widely applicable approach. the use of tailored dvds is practical, feasible, and inexpensive enough to be attractive to clinics serving low-income and minority women. a large number of video segments will be produced utilizing live actors, animation, and word slates. about 10 segments will be computer-selected for the videos for each woman based on her responses to four self-assessments. no studies to date have included multiple doses of tailored video education, or used dvds in this way. design narrative: this two-arm randomized study is designed to develop and evaluate the efficacy of five tailored dvds in reducing exposure to ets among low-income pregnant/postpartum women. the overall purposes of the study are 1) to develop an innovative intervention (tailored "take-home" dvds) to help pregnant women maximize their pregnancy outcome and their new infant's health through reduction in exposure to ets and 2) to study the feasibility and efficacy of this intervention compared with a usual care group. this innovative technology will be field tested in collaboration with six prenatal clinics that serve primarily low-income, african american, latina, and minority women to address two specific aims. specific aim 1: to test the efficacy of tailored video (tv) versus usual care (uc) approaches in terms of reducing the ets exposure among fetuses of nonsmoking, low-income women during pregnancy (assessed at 34 weeks gestation using saliva cotinine concentration and ets self-report) and among infants (as measured by saliva cotinine concentration and mothers' self-reports at 6 months postpartum). specific aim 2: to test the efficacy of tv versus uc approaches in terms of reducing the exposure of the fetuses of low-income, smoking women to tobacco smoke during pregnancy (assessed at 34 weeks gestation using saliva cotinine concentrations of the pregnant women and smoking and ets self-reports) and to their infants (as measured by saliva cotinine concentration from the infant at 6 months postpartum and self-reports of infant exposure by the new mothers). because of the lack of data on reducing ets exposure amongst low-income and minority women, intensive formative and extensive process evaluation components are included.

Eligibility criteria:
inclusion criteria: * women who attend their first prenatal visit by 16 weeks gestation * women exposed to tobacco smoke daily exclusion criteria: * women expecting complications or multiple births
a double-blind, multiple ascending dose study to assess safety, tolerability and pharmacokinetics of dx-2930 in hereditary angioedema participants

Conditions: Hereditary Angioedema (HAE)

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (pk) profile of multiple subcutaneous administrations of dx-2930 across a range of doses in hae participants.


Eligibility criteria:
inclusion criteria: * at least 18 years of age at the time of screening * documented diagnosis of hae (type i or ii) * experiencing ≥2 hae attacks per year, with at least 1 attack in the past 6 months reported by the participant * willing and able to read, understand, and sign an informed consent form * females of childbearing potential must agree to be abstinent or else use acceptable forms of contraception throughout study * males with female partners of childbearing potential must agree to be abstinent or use a medically acceptable form of contraception throughout study exclusion criteria: * exposure to an investigational drug or device within 90 days prior to study * history of exposure within the past 5 years to a monoclonal antibody or recombinant protein bearing an fc domain * concomitant diagnosis of another form of chronic angioedema * use of long-term prophylaxis for hae within 90 days prior to study * use of c1-inh that exceeds a total of 30 days within the past 90 days prior to study; any use of c1-inh within 7 days prior to study * exposure to angiotensin-converting enzyme (ace) inhibitors or any estrogen-containing medications with systemic absorption within 90 days prior to study * exposure to androgens within 90 days prior to study * presence of an indwelling catheter * diagnosis of hiv * active liver disease or liver function test abnormalities * history of substance abuse or dependence * pregnancy or breastfeeding * any condition that, in the opinion of the investigator, may compromise their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results

Keywords: hae
analgesic treatment mediated by arcoxia (0663-093)

Conditions: Pain

Summary: allow physicians to test the efficacy of arcoxia in patients with acute pain.


Eligibility criteria:
inclusion criteria: * diagnosis of acute pain susceptible of pharmacological treatment * greater than 18 years of age * voluntary acceptance to participate in the study and signature of the informed consent form exclusion criteria: * allergy to etoricoxib or any of its components * less than 18 years old * patient is taking anticoagulants * patient that already has taken any drug as analgesic
multi-center clinical trials of sanjie analgesic capsule in treating endometriosis

Conditions: Dysmenorrhea

Summary: it is a multi-center, double -blind, placebo -controlled, randomized post-marketing study in chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with sanjie analgesic capsule versus subjects treated with placebo.

sanjie analgesic capsule is a chinese traditional patent medicine. it is a botanical extract from the raw materials of the resina draconis , panax notoginseng, fritillary bulb and coix seed, which are derived from a classic prescription of traditional chinese medicine. sanjie analgesic capsule was approved by cfda in 2004, produced by means of modern technology by jiangsu kanion pharmaceutical co., ltd. the study is a multi-center, double -blind, placebo-controlled, randomized in chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with sanjie analgesic capsule versus subjects treated with placebo.

Eligibility criteria:
inclusion criteria: * subjects have a diagnosis of endometriosis by laparoscopy within 5 years prior to signing icf, main complain of dysmenorrhea (or menstrual pain or painful periods) and with vas score of 4 or above; endometriosis combined with uterine adenomyosis is included. * female between the ages of 18 and 45 years old; * regular menstrual period, menstrual cycle falls in the ranging from 28 to 30 days; * no pregnancy planning during taking study medication; use (or have their partner use) an acceptable method of birth control within the projected duration of the study ; * subjects must sign icf and agree for follow up. exclusion criteria: * genital cancer or other malignant tumor; * adnexal masses≥5cm; * uterine myoma≥3cm; * suffering from cardiovascular, hepatic, renal or hematopoietic system disease or mental illness; * receiving hormone therapy within 3 months prior to signing icf; * receiving surgical treatment for endometriosis within 3 months prior to signing icf; * subjects have a plan of pregnancy, being pregnant, breast-feeding during recent 3 months.

Keywords: endometriosis dysmenorrhea sanjie analgesic capsule effect/safety
evaluation of a non-invasive electrocardiogram-assisted blood pressure monitor

Conditions: Hypertension; Atrial Fibrillation; Obesity; Heart Failure; Atherosclerosis

Summary: approximately one billion people suffer from hypertension worldwide. at least 10% of this population, that is, 100 million people, also suffers from associated chronic conditions namely, atrial fibrillation (af), obesity, arterial stiffness (as), and heart failure (hf). personal interaction with medical practitioners (doctors) and review of published clinical research confirms that current non-invasive automatic blood pressure (bp) monitors that rely on bp pulse analysis alone cannot provide accurate measurement due to the unpredictable/weak nature of bp pulses in the above-mentioned chronic conditions. lack of accuracy in bp estimation can lead to wrong diagnoses and hence to complications such as stokes and heart attacks. the sponsor is developing a novel non-invasive bp monitor that is similar to existing automatic monitors yet is capable of acquiring and analyzing electrocardiogram (ecg) data in conjunction with bp pulse data to provide better and more accurate measurements in the above chronic conditions. the objective of this clinical trial is to evaluate the performance of this ecg-assisted bp monitor against invasive bp measurements in a small group of patients who suffer from the above conditions.


Eligibility criteria:
inclusion: 1. patients undergoing an angiography in the catheterization lab who also suffer from at least one of the following chronic conditions: * established diagnosis of af. * obesity characterized by a bmi \> 40 (extremely high, class iii). * established diagnosis of as. * established diagnosis of hf. 2. age ≥ 18 years. exclusion: 1. patients unwilling or unable to comply with study requirements. 2. failure to sign the informed consent form. 3. age \< 18 years.
brain scintigraphy in normal versus kleine-levin syndrome subjects

Conditions: Healthy Subjects; Kleine-Levin Syndrome

Summary: the investigators perform neuropsychological tests and brain scintigraphy in 30 healthy subjects. these results will be compared with data obtained out of episode in patients with kleine-levin syndrome (kls). the investigators want to determine if brain functional imaging and cognitive abnormalities persist during asymptomatic period in a large series of patients with kls, and to find predictors of these abnormalities.

3 steps in the protocol : * brain ecd-spect (marking brain perfusion in relation to brain active/hypoactive area) superimposed on a template t1-weighted brain mri. * extensive cognitive tests of executive functions, verbal memory and fluency , visuospatial ability and memory, reasoning abilities: spontaneous memory complaint, stroop color word test, trail making test a and b, direct and reverse digit span test, letter and semantic fluency test, free and cued selective reminding test, rey-osterrieth complex figure, mini-mental test, progressive matrice of raven (pm-38) * kls-inventory and face to face interview of patients and parents by neurologist for patients. modified kls-inventory for healthy subjects. main outcome : number of patients with persisting hypoperfused brain area (compared to controls), location of these area, number of patients with at least -1sd in one cognitive domain correlation between kls severity (disease course, number of episode, mean duration of episodes, time incapacitated, number of symptoms) and brain perfusion and cognitive abnormalities

Eligibility criteria:
inclusion criteria : * subjects males and females with more than 18 y.o, age and sex-matched with patients with kleine-levin syndrome * with the same educational level and dominant hand than patients with kleine-levin syndrome * without any brain disease or sleep disease (epworth score \< 11/24) known. * with social security * french language * for women : nonpregnant taking effective contraception exclusion criteria : * minor subjects * adults under protection * subjects with neurologic, psychiatric, somatic or sleep diseases and/or receiving a psychotropic medication interfering with the results. * subjects with history of seizures or loss of consciousness * subjects with excessive alcohol consumption (more than 3 doses /day) * subjects without any social security * subjects non fluent in french * for women : no effective contraception or lactation period

Keywords: brain scintigraphy
clinical study to assess the efficacy and safety of at-5214 in the treatment of subjects with palmar hyperhidrosis

Conditions: Hyperhidrosis; Palmar Hyperhidrosis

Summary: this is a multicenter, randomized, double-blind, placebo-controlled, parallel group comparison study of at-5214 in subjects with moderate to severe primary palmar hyperhidrosis (sweaty palms). this study will compare two different oral (tablet) doses of at-5214 (study drug) versus a matched placebo. approximately 120 subjects will be enrolled at approximately 10 study sites.


Eligibility criteria:
inclusion criteria: * subject has a clinical diagnosis of primary hyperhidrosis of the palms * subject is currently drug-naïve for hyperhidrosis medications * females must be post-menopausal, surgically sterile, or use an effective method of birth control exclusion criteria: * subject is pregnant, lactating, is planning to become pregnant during the study, or is less than one year postpartum. * subject is a user of nicotine products within one year prior to visit 1/screening. * subject has known history of secondary hyperhidrosis. * subject has existence of neurological, psychiatric, endocrine, or other disease that can cause secondary hyperhidrosis or affect sweating. * subject has known history of sjögren's syndrome or sicca syndrome. * subject has used any of the following hyperhidrosis medications or therapies within the specified timeframe: 1. iontophoresis to the palms within four weeks prior to baseline visit; 2. botulinum toxin to the palms within one year prior to baseline visit; 3. prior surgical procedures to the palms (e.g., sympathectomy, debulking of sweat glands); 4. prior medical device treatment to the palms (approved or investigational); 5. any prescription treatments for hyperhidrosis within four weeks prior to baseline visit. 6. any topical antiperspirant treatment to the palms within 7 days prior to baseline visit. * subject is currently enrolled in an investigational drug or device study. * subject has previously participated in a clinical study of dexmecamylamine or tc-5214. * subject has used an investigational drug or investigational device treatment within 30 days prior to baseline.

Keywords: sweaty palms